Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis

Scolaris Content Display Scolaris Content Display

Ir a:

Figure 1

PRISMA flow diagram

Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Analysis 1.1

Comparison 1 Inhaled antibiotics compared to control, Outcome 1 Need for hospital admission.

Analysis 1.2

Comparison 1 Inhaled antibiotics compared to control, Outcome 2 Need for additional IV antibiotics.

Analysis 1.3

Comparison 1 Inhaled antibiotics compared to control, Outcome 3 Adverse events.

Analysis 1.4

Comparison 1 Inhaled antibiotics compared to control, Outcome 4 Development of resistant organisms.

Comparison 1. Inhaled antibiotics compared to control

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Need for hospital admission Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

1.1 At 1 to 2 weeks	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Need for additional IV antibiotics Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

2.1 At 1 to 2 weeks	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Adverse events Show forest plot	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

3.1 Renal toxicity	2	46	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Development of resistant organisms Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

4.1 At 1 to 2 weeks	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 1. Inhaled antibiotics compared to control